Genomic Press
@genomicpress.bsky.social
Genomic Press is a world-class neuroscience publishing platform, providing the most exciting emerging science unparalleled visibility.
Publisher: Julio Licinio, MD, PhD, MBA, MS.
https://genomicpress.com/
https://media.genomicpress.com/
Publisher: Julio Licinio, MD, PhD, MBA, MS.
https://genomicpress.com/
https://media.genomicpress.com/
9/9
Paper is 100% open access — go read it right now:
🔗 doi.org/10.61373/gp0...
Massive congrats to Karthikeyan Tangavelou, Kiran Bhaskar, Francesca-Fang Liao and team!
This one is going to run.
#Alzheimers #Tau #Neuroscience #Brain #Biotech
Paper is 100% open access — go read it right now:
🔗 doi.org/10.61373/gp0...
Massive congrats to Karthikeyan Tangavelou, Kiran Bhaskar, Francesca-Fang Liao and team!
This one is going to run.
#Alzheimers #Tau #Neuroscience #Brain #Biotech
November 29, 2025 at 6:24 PM
9/9
Paper is 100% open access — go read it right now:
🔗 doi.org/10.61373/gp0...
Massive congrats to Karthikeyan Tangavelou, Kiran Bhaskar, Francesca-Fang Liao and team!
This one is going to run.
#Alzheimers #Tau #Neuroscience #Brain #Biotech
Paper is 100% open access — go read it right now:
🔗 doi.org/10.61373/gp0...
Massive congrats to Karthikeyan Tangavelou, Kiran Bhaskar, Francesca-Fang Liao and team!
This one is going to run.
#Alzheimers #Tau #Neuroscience #Brain #Biotech
8/9
New reality
OTULIN sits at the ROOT of tau expression.
Partial inhibition → lowers toxic phospho-tau in real Alzheimer’s neurons
Total knockout → erases tau completely
Brand-new, fully druggable target for Alzheimer’s, FTD, PSP, CBD…
New reality
OTULIN sits at the ROOT of tau expression.
Partial inhibition → lowers toxic phospho-tau in real Alzheimer’s neurons
Total knockout → erases tau completely
Brand-new, fully druggable target for Alzheimer’s, FTD, PSP, CBD…
November 29, 2025 at 6:24 PM
8/9
New reality
OTULIN sits at the ROOT of tau expression.
Partial inhibition → lowers toxic phospho-tau in real Alzheimer’s neurons
Total knockout → erases tau completely
Brand-new, fully druggable target for Alzheimer’s, FTD, PSP, CBD…
New reality
OTULIN sits at the ROOT of tau expression.
Partial inhibition → lowers toxic phospho-tau in real Alzheimer’s neurons
Total knockout → erases tau completely
Brand-new, fully druggable target for Alzheimer’s, FTD, PSP, CBD…
7/9
First author Karthikeyan Tangavelou:
“We thought inhibiting OTULIN would help clear toxic tau…
…instead the results completely overturned our expectations.”
The best discoveries come when your hypothesis gets bodied.
First author Karthikeyan Tangavelou:
“We thought inhibiting OTULIN would help clear toxic tau…
…instead the results completely overturned our expectations.”
The best discoveries come when your hypothesis gets bodied.
November 29, 2025 at 6:24 PM
7/9
First author Karthikeyan Tangavelou:
“We thought inhibiting OTULIN would help clear toxic tau…
…instead the results completely overturned our expectations.”
The best discoveries come when your hypothesis gets bodied.
First author Karthikeyan Tangavelou:
“We thought inhibiting OTULIN would help clear toxic tau…
…instead the results completely overturned our expectations.”
The best discoveries come when your hypothesis gets bodied.
6/9
Media lost their minds in <72 hours
Already on MSN.com (US + UK), AP news wire (worldwide), Medical Xpress, Drug Target Review + Spanish/Portuguese -language outlets
Screenshot proof 👇
Media lost their minds in <72 hours
Already on MSN.com (US + UK), AP news wire (worldwide), Medical Xpress, Drug Target Review + Spanish/Portuguese -language outlets
Screenshot proof 👇
November 29, 2025 at 6:24 PM
6/9
Media lost their minds in <72 hours
Already on MSN.com (US + UK), AP news wire (worldwide), Medical Xpress, Drug Target Review + Spanish/Portuguese -language outlets
Screenshot proof 👇
Media lost their minds in <72 hours
Already on MSN.com (US + UK), AP news wire (worldwide), Medical Xpress, Drug Target Review + Spanish/Portuguese -language outlets
Screenshot proof 👇
5/9
RNA-seq on OTULIN-KO cells = absolute carnage
↓ 13,341 genes
↑ 774 genes
43,003 RNA transcripts wrecked
OTULIN is secretly one of the master regulators of RNA life & death in neurons. Nobody saw this coming.
RNA-seq on OTULIN-KO cells = absolute carnage
↓ 13,341 genes
↑ 774 genes
43,003 RNA transcripts wrecked
OTULIN is secretly one of the master regulators of RNA life & death in neurons. Nobody saw this coming.
November 29, 2025 at 6:24 PM
5/9
RNA-seq on OTULIN-KO cells = absolute carnage
↓ 13,341 genes
↑ 774 genes
43,003 RNA transcripts wrecked
OTULIN is secretly one of the master regulators of RNA life & death in neurons. Nobody saw this coming.
RNA-seq on OTULIN-KO cells = absolute carnage
↓ 13,341 genes
↑ 774 genes
43,003 RNA transcripts wrecked
OTULIN is secretly one of the master regulators of RNA life & death in neurons. Nobody saw this coming.
4/9
CRISPR knockout of OTULIN = nuclear option
Result:
→ Total tau protein undetectable
→ MAPT mRNA (the gene) undetectable on qPCR
→ Zero cell death, perfect neuronal morphology
Tau was never even transcribed.
CRISPR knockout of OTULIN = nuclear option
Result:
→ Total tau protein undetectable
→ MAPT mRNA (the gene) undetectable on qPCR
→ Zero cell death, perfect neuronal morphology
Tau was never even transcribed.
November 29, 2025 at 6:24 PM
4/9
CRISPR knockout of OTULIN = nuclear option
Result:
→ Total tau protein undetectable
→ MAPT mRNA (the gene) undetectable on qPCR
→ Zero cell death, perfect neuronal morphology
Tau was never even transcribed.
CRISPR knockout of OTULIN = nuclear option
Result:
→ Total tau protein undetectable
→ MAPT mRNA (the gene) undetectable on qPCR
→ Zero cell death, perfect neuronal morphology
Tau was never even transcribed.
3/9
Patient-derived Alzheimer’s neurons normally have:
🔥 Sky-high OTULIN protein
🔥 Sky-high phospho-tau (AT8, AT180, PHF-1)
One new drug-like molecule (UC495) ➜ slashed pathogenic tau in these actual human AD neurons.
Patient-derived Alzheimer’s neurons normally have:
🔥 Sky-high OTULIN protein
🔥 Sky-high phospho-tau (AT8, AT180, PHF-1)
One new drug-like molecule (UC495) ➜ slashed pathogenic tau in these actual human AD neurons.
November 29, 2025 at 6:24 PM
3/9
Patient-derived Alzheimer’s neurons normally have:
🔥 Sky-high OTULIN protein
🔥 Sky-high phospho-tau (AT8, AT180, PHF-1)
One new drug-like molecule (UC495) ➜ slashed pathogenic tau in these actual human AD neurons.
Patient-derived Alzheimer’s neurons normally have:
🔥 Sky-high OTULIN protein
🔥 Sky-high phospho-tau (AT8, AT180, PHF-1)
One new drug-like molecule (UC495) ➜ slashed pathogenic tau in these actual human AD neurons.
2/9
They went in thinking:
“Block OTULIN → keep more ubiquitin on tau → cells clear toxic tangles faster.”
What actually happened when they knocked OTULIN out?
Tau protein = GONE
Tau mRNA = GONE
Neurons = still 100% happy and healthy
The brain simply stopped making tau.
They went in thinking:
“Block OTULIN → keep more ubiquitin on tau → cells clear toxic tangles faster.”
What actually happened when they knocked OTULIN out?
Tau protein = GONE
Tau mRNA = GONE
Neurons = still 100% happy and healthy
The brain simply stopped making tau.
November 29, 2025 at 6:24 PM
2/9
They went in thinking:
“Block OTULIN → keep more ubiquitin on tau → cells clear toxic tangles faster.”
What actually happened when they knocked OTULIN out?
Tau protein = GONE
Tau mRNA = GONE
Neurons = still 100% happy and healthy
The brain simply stopped making tau.
They went in thinking:
“Block OTULIN → keep more ubiquitin on tau → cells clear toxic tangles faster.”
What actually happened when they knocked OTULIN out?
Tau protein = GONE
Tau mRNA = GONE
Neurons = still 100% happy and healthy
The brain simply stopped making tau.
From Boston to Tokyo, Cambridge to São Paulo: we bring you inside the minds transforming brain science and medicine.
Check the interviews: interviews.genomicpress.com
Check the interviews: interviews.genomicpress.com
November 23, 2025 at 6:59 AM
From Boston to Tokyo, Cambridge to São Paulo: we bring you inside the minds transforming brain science and medicine.
Check the interviews: interviews.genomicpress.com
Check the interviews: interviews.genomicpress.com
What No One Else Has
Direct access to the scientists reshaping neuroscence, psychiatry, neurology, neurosurgery, neuro-oncology, genomics, and psychedelics.
Direct access to the scientists reshaping neuroscence, psychiatry, neurology, neurosurgery, neuro-oncology, genomics, and psychedelics.
November 23, 2025 at 6:59 AM
What No One Else Has
Direct access to the scientists reshaping neuroscence, psychiatry, neurology, neurosurgery, neuro-oncology, genomics, and psychedelics.
Direct access to the scientists reshaping neuroscence, psychiatry, neurology, neurosurgery, neuro-oncology, genomics, and psychedelics.
7/7
Clinical questions this raises:
Should patients avoid caffeine before ketamine/ECT treatments?
Does chronic coffee consumption actually help prevent depression?
Can we leverage adenosine dynamics as a treatment biomarker?
Brain Medicine: bm.genomicpress.com
Genomic Press: genomicpress.com
Clinical questions this raises:
Should patients avoid caffeine before ketamine/ECT treatments?
Does chronic coffee consumption actually help prevent depression?
Can we leverage adenosine dynamics as a treatment biomarker?
Brain Medicine: bm.genomicpress.com
Genomic Press: genomicpress.com
November 11, 2025 at 4:20 PM
7/7
Clinical questions this raises:
Should patients avoid caffeine before ketamine/ECT treatments?
Does chronic coffee consumption actually help prevent depression?
Can we leverage adenosine dynamics as a treatment biomarker?
Brain Medicine: bm.genomicpress.com
Genomic Press: genomicpress.com
Clinical questions this raises:
Should patients avoid caffeine before ketamine/ECT treatments?
Does chronic coffee consumption actually help prevent depression?
Can we leverage adenosine dynamics as a treatment biomarker?
Brain Medicine: bm.genomicpress.com
Genomic Press: genomicpress.com
6/7
THE COFFEE PARADOX ☕
Here's where it gets fascinating:
Coffee consumption → 20-25% reduced depression (protective through tonic adenosine receptor modulation)
BUT
Acute caffeine intake → may interfere with phasic adenosine surges during treatment
Same receptors, opposite clinical implications!
THE COFFEE PARADOX ☕
Here's where it gets fascinating:
Coffee consumption → 20-25% reduced depression (protective through tonic adenosine receptor modulation)
BUT
Acute caffeine intake → may interfere with phasic adenosine surges during treatment
Same receptors, opposite clinical implications!
November 11, 2025 at 4:20 PM
6/7
THE COFFEE PARADOX ☕
Here's where it gets fascinating:
Coffee consumption → 20-25% reduced depression (protective through tonic adenosine receptor modulation)
BUT
Acute caffeine intake → may interfere with phasic adenosine surges during treatment
Same receptors, opposite clinical implications!
THE COFFEE PARADOX ☕
Here's where it gets fascinating:
Coffee consumption → 20-25% reduced depression (protective through tonic adenosine receptor modulation)
BUT
Acute caffeine intake → may interfere with phasic adenosine surges during treatment
Same receptors, opposite clinical implications!
5/7
Non-pharmacological breakthrough:
Acute intermittent hypoxia (5 cycles of controlled oxygen reduction, 3 days) produces antidepressant effects entirely dependent on adenosine signaling.
Safe, non-invasive, scalable—especially valuable for low-resource settings. 🌍
Non-pharmacological breakthrough:
Acute intermittent hypoxia (5 cycles of controlled oxygen reduction, 3 days) produces antidepressant effects entirely dependent on adenosine signaling.
Safe, non-invasive, scalable—especially valuable for low-resource settings. 🌍
November 11, 2025 at 4:20 PM
5/7
Non-pharmacological breakthrough:
Acute intermittent hypoxia (5 cycles of controlled oxygen reduction, 3 days) produces antidepressant effects entirely dependent on adenosine signaling.
Safe, non-invasive, scalable—especially valuable for low-resource settings. 🌍
Non-pharmacological breakthrough:
Acute intermittent hypoxia (5 cycles of controlled oxygen reduction, 3 days) produces antidepressant effects entirely dependent on adenosine signaling.
Safe, non-invasive, scalable—especially valuable for low-resource settings. 🌍
4/7
Translation to therapeutics was immediate:
The team synthesized 31 ketamine derivatives and identified deschloroketamine (DCK): • Effective at 2 mg/kg (vs 10 mg/kg for ketamine)
• 40-80% stronger adenosine signals • Minimal psychomimetic side effects
Better therapeutic window = safer treatment 💊
Translation to therapeutics was immediate:
The team synthesized 31 ketamine derivatives and identified deschloroketamine (DCK): • Effective at 2 mg/kg (vs 10 mg/kg for ketamine)
• 40-80% stronger adenosine signals • Minimal psychomimetic side effects
Better therapeutic window = safer treatment 💊
November 11, 2025 at 4:20 PM
4/7
Translation to therapeutics was immediate:
The team synthesized 31 ketamine derivatives and identified deschloroketamine (DCK): • Effective at 2 mg/kg (vs 10 mg/kg for ketamine)
• 40-80% stronger adenosine signals • Minimal psychomimetic side effects
Better therapeutic window = safer treatment 💊
Translation to therapeutics was immediate:
The team synthesized 31 ketamine derivatives and identified deschloroketamine (DCK): • Effective at 2 mg/kg (vs 10 mg/kg for ketamine)
• 40-80% stronger adenosine signals • Minimal psychomimetic side effects
Better therapeutic window = safer treatment 💊
3/7
Key finding: It's NOT about NMDA receptors!
Ketamine acts by directly modulating mitochondrial metabolism → increasing intracellular adenosine → transporter-mediated release.
This happens WITHOUT neuronal hyperactivity, overturning assumptions about seizure-like activity being necessary.
Key finding: It's NOT about NMDA receptors!
Ketamine acts by directly modulating mitochondrial metabolism → increasing intracellular adenosine → transporter-mediated release.
This happens WITHOUT neuronal hyperactivity, overturning assumptions about seizure-like activity being necessary.
November 11, 2025 at 4:20 PM
3/7
Key finding: It's NOT about NMDA receptors!
Ketamine acts by directly modulating mitochondrial metabolism → increasing intracellular adenosine → transporter-mediated release.
This happens WITHOUT neuronal hyperactivity, overturning assumptions about seizure-like activity being necessary.
Key finding: It's NOT about NMDA receptors!
Ketamine acts by directly modulating mitochondrial metabolism → increasing intracellular adenosine → transporter-mediated release.
This happens WITHOUT neuronal hyperactivity, overturning assumptions about seizure-like activity being necessary.
2/7
Professor Min-Min Luo's team discovered that ketamine, ECT, and acute intermittent hypoxia—three completely different interventions—all work through the SAME mechanism: adenosine surges in mood-regulatory brain circuits.
Ketamine (10 mg/kg) triggered ~15% adenosine increases.
Professor Min-Min Luo's team discovered that ketamine, ECT, and acute intermittent hypoxia—three completely different interventions—all work through the SAME mechanism: adenosine surges in mood-regulatory brain circuits.
Ketamine (10 mg/kg) triggered ~15% adenosine increases.
November 11, 2025 at 4:20 PM
2/7
Professor Min-Min Luo's team discovered that ketamine, ECT, and acute intermittent hypoxia—three completely different interventions—all work through the SAME mechanism: adenosine surges in mood-regulatory brain circuits.
Ketamine (10 mg/kg) triggered ~15% adenosine increases.
Professor Min-Min Luo's team discovered that ketamine, ECT, and acute intermittent hypoxia—three completely different interventions—all work through the SAME mechanism: adenosine surges in mood-regulatory brain circuits.
Ketamine (10 mg/kg) triggered ~15% adenosine increases.
Full paper (open access): doi.org/10.61373/bm025...
Journal: bm.genomicpress.com
Publisher: genomicpress.com
This is what real-time scientific impact looks like in 2025. 🚀
Also: your gut bacteria are running more of your life than you think. Sleep well (with help from your microbiome).
(8/8)
Journal: bm.genomicpress.com
Publisher: genomicpress.com
This is what real-time scientific impact looks like in 2025. 🚀
Also: your gut bacteria are running more of your life than you think. Sleep well (with help from your microbiome).
(8/8)
November 5, 2025 at 11:36 AM
Full paper (open access): doi.org/10.61373/bm025...
Journal: bm.genomicpress.com
Publisher: genomicpress.com
This is what real-time scientific impact looks like in 2025. 🚀
Also: your gut bacteria are running more of your life than you think. Sleep well (with help from your microbiome).
(8/8)
Journal: bm.genomicpress.com
Publisher: genomicpress.com
This is what real-time scientific impact looks like in 2025. 🚀
Also: your gut bacteria are running more of your life than you think. Sleep well (with help from your microbiome).
(8/8)
For sleep researchers, this consolidates scattered findings into a coherent framework.
For clinicians, it points toward microbiome-based diagnostics and therapeutics.
For patients with chronic insomnia? Potentially transformative new treatment avenues.
(7/8)
For clinicians, it points toward microbiome-based diagnostics and therapeutics.
For patients with chronic insomnia? Potentially transformative new treatment avenues.
(7/8)
November 5, 2025 at 11:36 AM
For sleep researchers, this consolidates scattered findings into a coherent framework.
For clinicians, it points toward microbiome-based diagnostics and therapeutics.
For patients with chronic insomnia? Potentially transformative new treatment avenues.
(7/8)
For clinicians, it points toward microbiome-based diagnostics and therapeutics.
For patients with chronic insomnia? Potentially transformative new treatment avenues.
(7/8)
What's fascinating: this is a review article in a new, not-yet-indexed journal (Brain Medicine).
Yet it's achieving distribution that established journals would envy.
Quality content + smart PR + right amplifiers = traditional metrics don't always predict impact.
(6/8)
Yet it's achieving distribution that established journals would envy.
Quality content + smart PR + right amplifiers = traditional metrics don't always predict impact.
(6/8)
November 5, 2025 at 11:36 AM
What's fascinating: this is a review article in a new, not-yet-indexed journal (Brain Medicine).
Yet it's achieving distribution that established journals would envy.
Quality content + smart PR + right amplifiers = traditional metrics don't always predict impact.
(6/8)
Yet it's achieving distribution that established journals would envy.
Quality content + smart PR + right amplifiers = traditional metrics don't always predict impact.
(6/8)
Global coverage hitting everywhere:
🇺🇸 scienmag.com/new-study-unc...
🇮🇹 www.repubblica.it/salute/2025/...
🇫🇷 www.pourquoidocteur.fr/Articles/Que...
🇪🇸 www.eleconomista.es/salud-bienes...
🇨🇳 www.163.com/dy/article/K...
🇦🇿 baku.ws/en/this-is-i...
Real international reach, not just Anglosphere.
(5/8)
🇺🇸 scienmag.com/new-study-unc...
🇮🇹 www.repubblica.it/salute/2025/...
🇫🇷 www.pourquoidocteur.fr/Articles/Que...
🇪🇸 www.eleconomista.es/salud-bienes...
🇨🇳 www.163.com/dy/article/K...
🇦🇿 baku.ws/en/this-is-i...
Real international reach, not just Anglosphere.
(5/8)
November 5, 2025 at 11:36 AM
Global coverage hitting everywhere:
🇺🇸 scienmag.com/new-study-unc...
🇮🇹 www.repubblica.it/salute/2025/...
🇫🇷 www.pourquoidocteur.fr/Articles/Que...
🇪🇸 www.eleconomista.es/salud-bienes...
🇨🇳 www.163.com/dy/article/K...
🇦🇿 baku.ws/en/this-is-i...
Real international reach, not just Anglosphere.
(5/8)
🇺🇸 scienmag.com/new-study-unc...
🇮🇹 www.repubblica.it/salute/2025/...
🇫🇷 www.pourquoidocteur.fr/Articles/Que...
🇪🇸 www.eleconomista.es/salud-bienes...
🇨🇳 www.163.com/dy/article/K...
🇦🇿 baku.ws/en/this-is-i...
Real international reach, not just Anglosphere.
(5/8)
The viral moment: Eric Topol (Scripps Research EVP, Super Agers author, 680K followers) shared it.
His single post → 41,000 views of the paper.
That's the power of engaged science communication meeting genuinely interesting research.
(4/8)
His single post → 41,000 views of the paper.
That's the power of engaged science communication meeting genuinely interesting research.
(4/8)
November 5, 2025 at 11:36 AM
The viral moment: Eric Topol (Scripps Research EVP, Super Agers author, 680K followers) shared it.
His single post → 41,000 views of the paper.
That's the power of engaged science communication meeting genuinely interesting research.
(4/8)
His single post → 41,000 views of the paper.
That's the power of engaged science communication meeting genuinely interesting research.
(4/8)